Psyence Biomedical shares surge 31.18% premarket as sustainable ibogaine supply chain established with PsyLabs to advance mental health treatments.

Psyence Biomedical surged 31.18% in premarket trading following its announcement of a sustainable, GMP-compliant ibogaine supply chain established with PsyLabs. The partnership ensures ethical sourcing of high-potency iboga bark, critical for advancing clinical development of ibogaine therapies targeting substance use disorders. By securing pharmaceutical-grade ibogaine HCL and Total Alkaloid Extracts, the company strengthens its position as a leader in the emerging ibogaine sector, aligning with growing global interest in psychedelic-based mental health treatments. The emphasis on sustainability, cultural respect, and regulatory compliance addresses key market demands, bolstering investor confidence in its long-term viability and competitive edge. This strategic milestone directly supports the company’s clinical pipeline and reinforces its commitment to ethical innovation in the biopharmaceutical space.